Opinion|Videos|October 11, 2024
Meningococcal Infection and NMOSD
Author(s)Sean Pittock, MD
Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.
Advertisement
Video content above is prompted by the following:
- Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
- There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
2
SKY-0515 Demonstrates Dose-Dependent Reductions in Mutant Huntingtin Protein in Phase 1 Update
3
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
4
Exploring the Unmet Need for FDA-Approved Therapies in Stuttering: Gerald McGuire, MD
5